Half-Year 2022 Financial and Clinical Trials Update

gRED neuroscience and infectious diseases development programs Molecule Indication Prodromal to mild Alzheimer's disease semorinemab (RG6100)1 Mild-to-moderate Alzheimer's disease Phase # of patients Status Neuroscience FPI Q4 2017 || 457 Primary endpoint not met Q3 2020 || Roche CT Identifier NCT03289143 (TAURIEL) Data presented at CTAD 2020 One of two co-primary endpoints met Q3 2021 Data presented at CTAD 2021 FPI Q1 2019 272 The Open Label Extension is ongoing NCT03828747 (LAURIET) Infectious Diseases LepB inhibitor (RG6319) Complicated urinary tract infection 56 FPI Q1 2022 Partner: 1AC Immune 159

View entire presentation